Customize Consent Preferences

We use cookies to help you navigate efficiently and perform certain functions. You will find detailed information about all cookies under each consent category below.

The cookies that are categorized as "Necessary" are stored on your browser as they are essential for enabling the basic functionalities of the site. ... 

Always Active

Necessary cookies are required to enable the basic features of this site, such as providing secure log-in or adjusting your consent preferences. These cookies do not store any personally identifiable data.

No cookies to display.

Functional cookies help perform certain functionalities like sharing the content of the website on social media platforms, collecting feedback, and other third-party features.

No cookies to display.

Analytical cookies are used to understand how visitors interact with the website. These cookies help provide information on metrics such as the number of visitors, bounce rate, traffic source, etc.

No cookies to display.

Performance cookies are used to understand and analyze the key performance indexes of the website which helps in delivering a better user experience for the visitors.

No cookies to display.

Advertisement cookies are used to provide visitors with customized advertisements based on the pages you visited previously and to analyze the effectiveness of the ad campaigns.

No cookies to display.

Pfizer sees promising results from antibiotic combo for superbug infections – National | 24CA News

Health
Published 01.06.2023
Pfizer sees promising results from antibiotic combo for superbug infections – National | 24CA News

Pfizer Inc mentioned on Thursday information from late-stage trials confirmed its experimental mixture of antibiotics was efficient in treating lethal infections brought on by drug-resistant micro organism.

Deaths from antibiotic-resistant micro organism, also referred to as superbugs, have been on the rise globally, and well being regulators have known as for the event of newer therapies as resistance to older antibiotics grows.

The late-stage research in contrast the experimental mixture of the antibiotics aztreonam-avibactam (ATM-AVI) and present generic drug metronidazole with a mix of two older antibiotics – meropenem and colistin – to deal with difficult intra-abdominal infections and forms of hospital-acquired pneumonia.

Hospital-acquired pneumonia happens in sufferers at the very least two to 3 days after being admitted, or in those that have life-threatening lung infections with excessive mortality charges and who’re on mechanical respiratory machines.

Pfizer mentioned the info from the research exhibits the antibiotic mixture of ATM-AVI is efficient and well-tolerated in treating infections brought on by gram-negative micro organism.

Story continues under commercial


Click to play video: 'Antibiotic-resistant bacteria can spread through clouds, study finds'

Antibiotic-resistant micro organism can unfold by way of clouds, research finds


The remedy price in sufferers with difficult intra-abdominal infections with Pfizer’s mixture remedy, together with present generic drug metronidazole, was 76.4%, versus 74% utilizing the opposite antibiotics.

For sufferers with forms of hospital-acquired pneumonia and ventilator‐related pneumonia, the remedy price was 45.9% for Pfizer’s antibiotic mixture with metronidazole, versus 41.7% for different, older therapies.

The Centers for Disease Control and Prevention estimates that 2.8 million antimicrobial-resistant infections happen annually within the United States.
— Reporting by Leroy Leo and Sriparna Roy in Bengaluru; Editing by Pooja Desai

&copy 2023 Thomson Reuters